Publication or presentation of results from multicenter clinical trials: Evidence from an academic medical center

American Heart Journal

Volumn 153, Issue 4, 2007, Pages 674-680

  Turer, Aslan T ^a   Mahaffey, Kenneth W ^a   Compton, Kate L ^a   Califf, Robert M ^a   Schulman, Kevin A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FINANCIAL MANAGEMENT; FOLLOW UP; INSTITUTIONAL REVIEW; PEER REVIEW; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLICATION; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL;

CLINICAL TRIALS; FOLLOW-UP STUDIES; HUMANS; MULTICENTER STUDIES; PROSPECTIVE STUDIES; PUBLISHING;

EID: 33947305657     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.01.005     Document Type: Article

References (36)

1. Hrachovec J.B., and Wright J.M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA 286 (2001) 2398-2399
2. Whittington C.J., Kendall T., Fonagy P., et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363 (2004) 1341-1345
3. Psaty B.M., Furberg C.D., Ray W.A., et al. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 292 (2004) 2622-2631
4. Protocol No. IQ5-97-02-001: a double-blind, randomized, placebo-controlled, comparative study of celecoxib (SC-58635) for the inhibition of progression of Alzheimer's disease. Available at: http://www.clinicalstudyresults.org/documents/company-study_76_0.pdf. Accessed October 3, 2006.
5. Blumenthal D., Campbell E.G., Anderson M.S., et al. Withholding research results in academic life science: evidence from a national survey of faculty. JAMA 277 (1997) 1224-1228
6. Rennie D. Thyroid storm. JAMA 277 (1997) 1238-1243
7. Schulman K.A., Seils D.M., Timbie J.W., et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med 347 (2002) 1335-1341
8. Mello M.M., Clarridge B.R., and Studdert D.M. Academic medical centers' standards for clinical-trial agreements with industry. N Engl J Med 352 (2005) 2202-2210
9. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 263 (1990) 1385-1389
10. Rivara F.P., and Cummings P. Publication bias: the problem and some suggestions. Arch Pediatr Adolesc Med 156 (2002) 424-425
11. Steinbrook R. Gag clauses in clinical-trial agreements. N Engl J Med 352 (2005) 2160-2162
12. Toma M., McAlister F.A., Bialy L., et al. Transition from meeting abstract to full-length journal article for randomized controlled trials. JAMA 295 (2006) 1281-1287
13. Dickersin K., Min Y.I., and Meinert C.L. Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards. JAMA 267 (1992) 374-378
14. Easterbrook P.J., and Matthews D.R. Fate of research studies. J R Soc Med 85 (1992) 71-76
15. Stern J.M., and Simes R.J. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 315 (1997) 640-645
16. Hartling L., Craig W.R., Russell K., et al. Factors influencing the publication of randomized controlled trials in child health research. Arch Pediatr Adolesc Med 158 (2004) 983-987
17. Arrive L., Boelle P.Y., Dono P., et al. Subsequent publication of orally presented original studies within 5 years after 1995 RSNA Scientific Assembly. Radiology 232 (2004) 101-106
18. Ioannidis J.P. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 279 (1998) 281-286
19. Marx W.F., Cloft H.J., Do H.M., et al. The fate of neuroradiologic abstracts presented at national meetings in 1993: rate of subsequent publication in peer-reviewed, indexed journals. AJNR Am J Neuroradiol 20 (1999) 1173-1177
20. Weber E.J., Callaham M.L., Wears R.L., et al. Unpublished research from a medical specialty meeting: why investigators fail to publish. JAMA 280 (1998) 257-259
21. Krzyzanowska M.K., Pintilie M., and Tannock I.F. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 290 (2003) 495-501
22. Garland E.J. Facing the evidence: antidepressant treatment in children and adolescents. CMAJ 170 (2004) 489-491
23. Depressing research. Lancet 363 (2004) 1335
24. Emanuel E.J., Wendler D., and Grady C. What makes clinical research ethical?. JAMA 283 (2000) 2701-2711
25. Dowd M.D. Breaching the contract: the ethics of nonpublication of research studies. Arch Pediatr Adolesc Med 158 (2004) 1014-1015
26. Antes G., and Chalmers I. Under-reporting of clinical trials is unethical. Lancet 361 (2003) 978-979
27. Lexchin J.R. Implications of pharmaceutical industry funding on clinical research. Ann Pharmacother 39 (2005) 194-197
28. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS Study: a randomized controlled trial. JAMA 284 (2000) 1247-1255
29. Garattini S., and Liberati A. The risk of bias from omitted research. BMJ 321 (2000) 845-846
30. Curfman G.D., Morrissey S., and Drazen J.M. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-1528. N Engl J Med 353 (2005) 2813-2814
31. Blumenthal D., Causino N., Campbell E., et al. Relationships between academic institutions and industry in the life sciences: an industry survey. N Engl J Med 334 (1996) 368-374
32. Buchkowsky S.S., and Jewesson P.J. Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 38 (2004) 579-585
33. Steinbrook R. Commercial support and continuing medical education. N Engl J Med 352 (2005) 534-535
34. Dickersin K., and Rennie D. Registering clinical trials. JAMA 290 (2003) 516-523
35. Rennie D. Trial registration: a great idea switches from ignored to irresistible. JAMA 292 (2004) 1359-1362
36. Drazen J.M. Institutions, contracts, and academic freedom. N Engl J Med 347 (2002) 1362-1363